H.C. Wainwright Keeps a Buy Rating on Rexahn Pharma

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rexahn Pharma (NYSE MKT: RNN), with a price target of $19.50. The company’s shares closed on Friday at $2.21.

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -11.0% and a 36.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Rexahn Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.

See today’s analyst top recommended stocks >>

Based on Rexahn Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.07 million. In comparison, last year the company had a GAAP net loss of $21.61 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rexahn Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It dedicates to the discovery, development and commercialization of innovative treatments for cancer and other medical needs.